How much will GSK receive from the settlement with Pfizer and BioNTech?

Question

Accepted Answer

GSK to Receive US$370 Million Plus Royalties from Pfizer-BioNTech Settlement

GSK will receive a total of US$370 million as part of a settlement with Pfizer and BioNTech, which also includes a one-per cent royalty on future US sales of specific mRNA vaccine products. This agreement resolves ongoing legal disputes concerning mRNA technology.
Settlement Amount for GSK

GSK is set to receive a direct payment of US$370 million from Pfizer and BioNTech. This payment is part of a larger US$740 million settlement that also benefits CureVac.
Royalty Entitlements

In addition to the upfront payment, GSK will be entitled to a one-per cent royalty on US sales. This royalty specifically applies to flu, Covid-19, and related combination mRNA vaccine products.
Background of the Dispute

The legal disputes stemmed from CureVac's lawsuit against BioNTech in 2022, alleging infringement of patents related to mRNA technology used in the development of the Comirnaty coronavirus vaccine. GSK had been collaborating with CureVac on mRNA vaccine development since 2020.
Broader Impact of the Agreement

This settlement, which includes a framework for resolving patent disputes outside the US, brings an end to the legal challenges between CureVac and BioNTech ahead of BioNTech's planned acquisition of CureVac. While disputes continue in Germany, this agreement marks a significant step in resolving intellectual property conflicts within the mRNA vaccine sector.

Reading history

Hide →

This history is cleared when the page is closed.

How much will GSK receive from the settlement with Pfizer and BioNTech?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends